MONEY Eli Lilly’s Olumiant receives expanded alopecia indication for children 12 and up (LLY:NYSE) Sep 25, 2026 Finance Desk Nadzeya Haroshka/iStock via Getty Images The US FDA expanded the use of Eli Lilly’s (LLY) Olumiant (baricitinib) for severe alopecia areata to include children 12 years and older. Approval was based on 36-week data from the adolescent cohort of the phase 3 BRAVE-AA-PEDS study that Source link
